Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Subscribe To Our Newsletter & Stay Updated